GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomind Labs Inc (NEOE:BMND) » Definitions » Capex-to-Revenue

Biomind Labs (NEOE:BMND) Capex-to-Revenue : 0.00 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Biomind Labs Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Biomind Labs's Capital Expenditure for the three months ended in Sep. 2023 was C$0.00 Mil. Its Revenue for the three months ended in Sep. 2023 was C$0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


Biomind Labs Capex-to-Revenue Historical Data

The historical data trend for Biomind Labs's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomind Labs Capex-to-Revenue Chart

Biomind Labs Annual Data
Trend Dec21 Dec22
Capex-to-Revenue
- -

Biomind Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biomind Labs's Capex-to-Revenue

For the Biotechnology subindustry, Biomind Labs's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomind Labs's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomind Labs's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biomind Labs's Capex-to-Revenue falls into.



Biomind Labs Capex-to-Revenue Calculation

Biomind Labs's Capex-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

Biomind Labs's Capex-to-Revenue for the quarter that ended in Sep. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomind Labs  (NEOE:BMND) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Biomind Labs Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biomind Labs's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomind Labs (NEOE:BMND) Business Description

Traded in Other Exchanges
Address
Camino Saravia s/n, Pando Science and Technology Park, Pando Canelones, Canelones, URY, CP 91.000
Biomind Labs Inc is a biotech Research and Development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. Biomind is developing pharmaceutical sole and combined formulations of the main natural psychedelic molecules with the aim of identifying novel pharmaceutical compounds for treating a wide range of therapeutic indications.

Biomind Labs (NEOE:BMND) Headlines

No Headlines